Race on Weight-Loss Track: Johnson’s Olebotide NDA Accepted, Will It Reshape the Market Landscape?

Johnson Pharmaceuticals' self-developed GLP-1/GIP dual receptor agonist Olebotide injection has officially obtained acceptance for marketing authorization appli...